ALDH1L2 orchestrates redox–growth coupling in renal carcinoma: pan-cancer evidence and mechanistic validation of the ROS–Akt/mTOR/S6K axis

This study is the first to systematically untangle the divergent roles of <i>ALDH1L2</i> in KIRC, BLCA, and PRAD from a pan-cancer perspective combined with ex vivo experiments, suggesting that <i>ALDH1L2</i> may serve as an important molecule influencing tumor progression and the immune microenvironment, thereby providing a new potential target for the diagnosis and treatment of related cancers.